Oct. 23, 2018
Between
a shifting landscape where insurers are morphing into more than payers and
uncertainty of the midterm elections and the impact on health policy, there's a
lot on Matt Eyles plate. Eyles leads America's Health Insurance Plans, the
industry's largest trade group, and last week he sat down with Healthcare Dive
to talk about the organization's legislative priorities and how AHIP is seeking
to representing more than just insurers.
HEALTHCARE DIVE: What
do you see as the three biggest issues facing the industry this year?
MATT
EYLES:
For the rest of the year, I think the legislative priorities are really focused
on the health insurer tax that hits all different programs. [We
are] Trying to get that suspended for 2020 because if we don't then
either Medicare premiums or commercial premiums will go up or benefits have to
be cut. It hits small businesses particularly to the tune of several hundred
dollars of additional premiums, so that’s a big one.
The
second one is really ensuring that the changes to the Part D coverage gap
remain in place. Those were some changes that were made back in March under the
budget agreement. We think it's really important that those stay in place so
costs are lower for Medicare beneficiaries who rely on Part D and it doesn't
result in higher cost for taxpayers too.
What will be the
biggest changes to the industry if the Democrats take one chamber of Congress
in the midterms?
EYLES: I think that one of the
focus areas will really be the price of prescription drugs. There is a lot of
attention and momentum, the administration is acutely focused on prescription
drug pricing issues with their blueprint and have moved forward now with
proposed regulations on requiring price disclosure in direct-to-consumer
advertisements, we think that’s a really positive step. I think we're going to
have to focus on affordability, too.
When
you look at the overall cost of healthcare and within the context of the individual
market there might be some actions that we could move forward with. But I think
people will be really focused on affordability because we're at a point where
something needs to happen.
Large insurers have
left AHIP over the years, how does that change AHIP's strategy
on the Hill? Do you see yourself needing to grow the tent or becoming more
niche to the payers that are left?
EYLES: I think there is a
really great opportunity for us to represent the new developments that we see
across the industry with this move towards more vertical integration. We have a
number of plans already that are both providers and plans at the same time. I
think this is a trend of more integration, there is no reason that you should
have separate medical from separate pharmacy from separate behavioral health.
All of these are about getting our arms around the total cost of care, and ways
that we can make it more efficient and a simpler and better experience for
patients.
I
think what we're doing is very consistent with the direction that they're
heading and we certainly want to represent the entirety of the industry.
Will that include
having to change your name from America's Health Insurance Plans?
EYLES: I think we'll have to
think because if you're not just health insurance anymore, you need to think
about those things.
How worried are you
about the Texas lawsuit?
EYLES: We're very engaged in
tracking what's happening with the suit. I think many people know we filed an
amicus brief focusing on the significant disruption that would
happen across the entire healthcare system if the law were overturned. If it is
found unconstitutional, not only would it affect the individual market, which
would be significant, but it would undo Medicaid expansion. It would result in
changes to Medicare and the Part D coverage gap program that was put in place.
It would touch the entire healthcare system and be incredibly disruptive. We're
waiting to see what the initial decision is from the judge and we also
recognize we're probably just at a starting point in the process.
There is another court house that's working it's way through in Maryland and we'll see what happens and whether or not they get joined. We're certainly very mindful about what it might mean for people who have pre-existing conditions and who need access to coverage. So we'll be following it very closely.
Many had talked about
social determinants at AHIP's annual conference last week, but some had
voiced concern about how to execute on that and with a return on investment. What
should plans start with and is there a role for AHIP to play in answering those
questions?
EYLES: Some of the answer
depends on the population that you're serving.
I
think a good place to look is some of the innovations we're seeing in Medicare
Advantage. Even for the 2019 year, plans are out providing supplemental
benefits that they really haven't before whether it be nutrition, adult day
care. I think the takeaway is there is a great recognition by the industry that
this is a priority, and how it applies to your specific business or product
line may differ. There's a great role for AHIP to play both in terms of
identifying best practices and acting as a convener to answer some of these
important policy questions.
What do you think of
the short term plan alternatives from the Trump administration?
EYLES: We're still waiting to
see how that market evolves. The rules took effect Oct. 1 and we're still
trying to figure out what does that market really look like and what impact
will it have. The open enrollment period hasn't yet started for the 2019 year
in the individual market.
We
thought that there's a role for short-term plans in the market but they should
be short term and of limited duration. It's a little too early to evaluate the
actual impact.
Is there a role for
private payers in a Medicare for all system?
EYLES: Not as it's currently
being defined. That's really the challenge is that it’s really being positioned
as what I would characterize as a regression to the old Medicare
fee-for-service model and making that sort of the standard. That's a 1960s
benefit package.
It
really won't allow for the innovation that we've seen through Medicare
Advantage, through the private market, and in Medicaid. If you came to this
conference five years ago the types of care programs and innovations in terms
of adding social determinants, you wouldn't have heard that. I don't know that
you would hear that in a system that was so centralized and run essentially by
the government.
https://www.healthcaredive.com/news/ceo-matt-eyles-on-why-ahip-will-probably-have-to-change-its-name/540155/
No comments:
Post a Comment